Predict your next investment

NeuCyte company logo
HEALTHCARE | Drug Discovery

See what CB Insights has to offer


Series A | Alive

Total Raised


Last Raised

$6.7M | 3 yrs ago

About NeuCyte

NeuCyte is a biotechnology company focused on advancing the drug discovery process by using cell based target-identification and drug-discovery platforms. NeuCyte has created a proprietary platform that enables translatable neuroscience, allows for modeling neurological diseases, as well as phenotypic and target-based drug screens in a human context.

NeuCyte Headquarter Location

1230 Bordeaux Drive Sunnyvale

Sunnyvale, California, 94089,

United States

Latest NeuCyte News

NeuCyte Licenses Its Novel Neuronal Programming Technology to Enable Academic Research

Dec 3, 2018

News provided by Share this article SUNNYVALE, Calif., Dec. 3, 2018 /CNW/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced that it has entered a license agreement with Boston Children's Hospital. As part of the agreement, Boston Children's has obtained a non-exclusive license from NeuCyte to manufacture transcription factor Ngn2 programmed induced neurons. The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions. "We are pleased to license this advantageous technology that was originated from Dr. Thomas Südhof's laboratory at Stanford University," said Mustafa Sahin, MD, PhD, director of the Translational Neuroscience Center and Human Neuron Core at Boston Children's and professor of neurology at Harvard Medical School. "We hope this technology will enable us and other researchers to create a tool that closely resembles human biology in vitro and will become an important part of our effort to improve human health." "NeuCyte has the exclusive rights to Stanford's original neuronal induction technology and has further developed it to incorporate into our proprietary in vitro drug discovery platforms," said Jonathan Davila, PhD, Co-founder and CEO of NeuCyte. "We are happy to get the technology into the hands of Boston Children's Hospital where it can be further used for academic research. We also welcome discussions with other organizations who are interested in this technology." About NeuCyte, Inc. NeuCyte is an innovative biotechnology company focused on developing impactful medicines for improving the lives of patients suffering from neurological disorders. Based on its proprietary SynFire® technology for generating human induced pluripotent stem cell (iPSC)-derived induced neural cells, NeuCyte has developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. With the vast knowledge brought by its staff and scientific advisory board, NeuCyte is actively pursuing drug discovery programs for the treatment of Fragile X Syndrome, Epilepsy, ALS and more. Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NeuCyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuCyte is included in 3 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.



2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.



5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

NeuCyte Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NeuCyte Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.